BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Leads Research and Manufacture of Beneficial Plant-Based Formulations

Healthy Extracts (OTCQB: HYEX) has continued to strengthen its stronghold in the health and lifestyle industry by researching and manufacturing plant-based formulations offering supplements that are beneficial for heart and nerve health. HYEX has broadened its portfolio through acquisitions of unique assets, BergaMet North America and Ultimate Brain Nutrients (“UBN”). “Healthy Extracts Inc. recently announced positive results of clinical studies for two leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster,” reads a recent article. “Duke Pitts, CEO of BergaMet North America, stated that HERHEART(TM) is a natural supplement that is scientifically formulated specifically for women to support cardiovascular health, including perimenopausal symptoms… The company’s UBN subsidiary released its study of Fuel4Thought(TM) Brain Booster, showing impressive results in brain activation, sports vision, hand to eye coordination and auditory reaction time.”

To view the full article, visit https://ibn.fm/20oD8

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending.

For more information visit: www.HealthyExtractsinc.com, www.BergametNA.com or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy 

Soligenix (NASDAQ: SNGX) announced the publication of positive results from its comparability study evaluating HyBryte(TM) versus Valchlor(R) for the treatment…

3 hours ago

BioMedNewsBreaks — NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) Wins BOLD Awards VII Healthcare Honor, Engages IBN For Investor Outreach 

This article has been disseminated on behalf of NurExone Biologic and may include paid advertising.  NurExone Biologic (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) announced…

4 hours ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced a strategic partnership with TechForce Robotics to advance commercialization of…

4 hours ago

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year 

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the…

1 day ago

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) ‘Significant Turning Point’ Spotlighted in Recent Article

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed Joseph Gunnar & Co.’s…

2 days ago

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

Soligenix (NASDAQ: SNGX) reported 2025 results highlighting progress across its rare disease pipeline, including advancing…

2 days ago